The COVID-19 Cytokine Storm; What We Know So Far
Autor: | Rasha Tolba Khattab, Ramy M. Salem, Haitham Salah Eldin, Dina Ragab, Mohamed Taeimah |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
lcsh:Immunologic diseases. Allergy ARDS medicine.medical_treatment Pneumonia Viral Immunology Review Antibodies Monoclonal Humanized Proinflammatory cytokine 03 medical and health sciences Betacoronavirus 0302 clinical medicine Pandemic medicine cytokine Immunology and Allergy Humans Interleukin 6 Pandemics Respiratory Distress Syndrome IL-6 biology business.industry Interleukin-6 SARS-CoV-2 COVID-19 medicine.disease Receptors Interleukin-6 COVID-19 Drug Treatment Pneumonia 030104 developmental biology Cytokine medicine.anatomical_structure biology.protein Cytokines storm Cytokine storm business Coronavirus Infections Cytokine Release Syndrome lcsh:RC581-607 030215 immunology Respiratory tract |
Zdroj: | Frontiers in Immunology, Vol 11 (2020) Frontiers in Immunology |
ISSN: | 1664-3224 |
DOI: | 10.3389/fimmu.2020.01446/full |
Popis: | COVID-19 is a rapidly spreading global threat that has been declared as a pandemic by the WHO. COVID-19 is transmitted via droplets or direct contact and infects the respiratory tract resulting in pneumonia in most of the cases and acute respiratory distress syndrome (ARDS) in about 15 % of the cases. Mortality in COVID-19 patients has been linked to the presence of the so-called "cytokine storm" induced by the virus. Excessive production of proinflammatory cytokines leads to ARDS aggravation and widespread tissue damage resulting in multi-organ failure and death. Targeting cytokines during the management of COVID-19 patients could improve survival rates and reduce mortality. |
Databáze: | OpenAIRE |
Externí odkaz: |